Our mission is to facilitate sustainable access to effective gene therapies for treatment of patients with ultra-rare diseases in Europe focusing on Inborn Errors of Immunity (IEI) and Inborn Errors of Metabolism (IEM).

In recent years it has become evident that effective stem cell gene therapies are not reaching patients in need for non-medical reasons. To achieve sustainable and affordable access to these life-changing gene therapies for patients with rare inherited diseases (r)evolution is needed to provide alternatives for the conventional commercialization model when not fit for purpose.